The rapid expansion of personalised medicine, driven by the genomics revolution, will in part depend on new generation biosensors and biomarkers - a major focus at NetScientific. The outcome will improve patient care while the shift from centralised labs to point-of-care testing will transform costs to healthcare providers and insurers. NetScientific's investments in quantitative diagnostics will produce lower cost, real-time detection with enhanced sensitivity and improved accuracy.
Advanced BioSensors, a subsidiary of NetScientific, is developing a small, portable, handheld nano-detection and monitoring device that will provide real-time measurement of biomarkers in biological samples. Initial applications are in infectious disease diagnosis and monitoring.
Cardiovascular Risk Diagnostic
NetScientific is developing an improved cholesterol test for better assessment of cardiovascular risk at the point-of-care.
Novel RNA Library for Gene Silencing
A NetScientific subsidiary is funding the development of a novel sh-RNA library for gene silencing and drug discovery applications.
Circulating Cancer Cell Test
NetScientific is working with researchers to develop a novel device for the isolation and detection of circulating tumour cells (CTCs). This new technique has great potential for early-stage cancer diagnosis, as well as effective monitoring of treatment efficacy and disease recurrence.
Cuffless Blood Pressure Monitor
Advanced BioSensors, a subsidiary of NetScientific, is developing an accurate and reliable cuff-less, non-invasive and self-calibrating blood pressure sensor for home and professional use.
QLIDA Inc., a NetScientific company, is developing inexpensive and effective in-vitro diagnostic tests to detect life-threatening conditions such as cancer and cardiovascular disease.
Skin Damage Biomarker
NetScientific has invested in research into a potentially ubiquitous biomarker of skin UV damage, with potential applications in cosmeceuticals, cancer surgery and drug development.